In March 2026, Tavneos FDA warnings about liver side effects and some death cases were issued, just a couple of months after the FDA had requested that Amgen recall Tavneos for drug safety reasons. According to the FDA, Tavneos (avacopan) is used together with glucocorticoids and other … More
Main Navigation Menu
➤ Current Drug Injury Lawsuits / Pharmaceutical Litigations
➤ Drug Injury Case Evaluation – Free. Confidential. No Obligation.
➤ Information About the Law Offices of Thomas J. Lamb
➤ Questions New Clients Have Asked Us (FAQs)
➤ Patient Resources: Medical Sites and More
➤ Recent Side Effects Blog Articles
➤ Collection of Earlier Blog Articles
To save time, you can use our Quick Contact Form to tell us about your possible case.
Recent News & Case Reports
Ozempic and Wegovy NAION Study 2026 Report: Two New Findings
A recent Ozempic and Wegovy NAION study made two new findings about people who used Ozempic or Wegovy and then were diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION) as a drug side effect that caused vision loss. The first is that the Wegovy NAION rate is five times that of … More
Ozempic-NAION Warnings Should Be In January 2026 Drug Label For New Pill Version
We have written about the Ozempic-NAION side effect drug safety issue several times over the past year-and-a-half, and have repeatedly pointed out that NAION is linked to semaglutide, the active ingredient in the currently available Novo Nordisk semaglutide medicines: Ozempic injection, Wegovy … More
Ozempic NAION Risk 200% Higher Than Some Other Diabetes Drugs
The semaglutide-containing drug Ozempic has been linked to non-arteritic anterior ischemic optic neuropathy (NAION). A 2026 medical journal article reported that the Ozempic NAION risk 200% higher than that of some other diabetes drugs, such as Invokana (canagliflozin), Jardiance (empagliflozin), … More
Rybelsus Pancreatitis Warnings and Rybelsus Drug Injury Lawsuits
Rybelsus Pancreatitis Warnings In October 2025, warnings about pancreatitis were added to the Rybelsus “drug label”. Insofar as there were no Rybelsus pancreatitis warnings until October 2025, there is a possible “failure to warn” products liability claim for people who were diagnosed with Rybelsus … More
Depo-Provera Label Change In 2025 Added Meningioma Warning
In a significant development regarding warnings about side effects associated with Depo-Provera injections, an FDA-ordered change to the Depo-Provera drug label added a meningioma warning in December 2025. Put differently, before this Depo-Provera label change, there was no meningioma warning in … More